Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06609889 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease

Study acronym: Lafora
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Start date changed from estimate of Dec 1, 2024 to Dec 3, 2024v3
  3. Start date: Oct 1, 2024 to Dec 1, 2024v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will test the safety and efficacy of multiple doses of ION283 administered as intrathecal (IT) injections by lumbar puncture (LP). All subjects will receive ION283. The dose level of 15 mg will be studied in all subjects.
Trial Details
NCT Number NCT06609889
Lead Sponsor Berge Minassian
Collaborators: Elpida Therapeutics SPC
Conditions
(from sponsor)		 Lafora Disease
Related terms Lafora Disease
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov